One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1706 articles with Amgen
First Amgen Collaboration With Academic Medical Center Focused on Research, Health Service Redesign and Outcomes-Based Care
Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
New Resources Available at MyelomaExplained.com Help Patients Set Goals and Prepare for Discussion With Doctor to Create Individualized Treatment Plan
AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients
Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).
Orchard Therapeutics, today announced the appointment of Joanne Beck, Ph.D., to its board of directors.
Has the U.S. Food and Drug Administration failed to do its due diligence in finding and reporting financial conflicts of interest between members of its scientific advisory committees and pharmaceutical companies?
The U.S. Food and Drug Administration withdrew its draft guidance on statistical methods to evaluate the analytical similarity between branded drugs and biosimilars.
Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Health Canada approves Amgen's Repatha (evolocumab) to reduce the risk of cardiovascular events in adults with Atherosclerotic Cardiovascular Disease
Amgen Canada announced that Health Canada has now indicated Repatha as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease.
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
Teva has a new headache. As the company pushes forward with its cost-cutting strategies, the company reported it is scrapping its chronic cluster headache program with fremanezumab.
In a brief statement, Mylan reported that the U.S. Food and Drug Administration (FDA) had informed the company that its Generic Advair Diskus had “minor deficiencies” that would be in a Complete Response Letter.
lobal marketing and communications services provider Williams Lea Tag has announced a partnership with Amgen.
Billionaire biotech entrepreneur Patrick Soon-Shiong has his eyes set on taking his newly formed oncology-focused Nant public this year.